# OnCo record anti-egfr-rechallenge (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/anti-egfr-rechallenge/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "anti-egfr-rechallenge" ;
  schema:name "Anti-EGFR rechallenge"@en ;
  schema:alternateName "EGFR rechallenge"@en, "cetuximab rechallenge"@en, "panitumumab rechallenge"@en, "chemotherapy-free interval"@en, "liquid biopsy-guided rechallenge"@en ;
  schema:description "When an EGFR antibody stops working, the resistant cells that caused it fade away once the drug is withdrawn. Rechallenge means giving the same class of drug again later, after a blood test has confirmed those resistant clones have receded, and in small trials about a fifth to a third of patients respond a second time."@en ;
  schema:url <https://onco.cc/terms/anti-egfr-rechallenge/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Cetuximab> ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2018.5080>, <https://doi.org/10.1038/s41591-022-01886-0>, <https://doi.org/10.1056/nejmoa1305275> ;
  onco:tag "gi", "colorectal" ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/colon-cancer/>, <https://onco.cc/cancers/rectal-cancer/> ;
  onco:technologies <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/braf/> ;
  onco:drugs <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/panitumumab/> ;
  onco:terms <https://onco.cc/terms/extended-ras-testing/>, <https://onco.cc/terms/sidedness/>, <https://onco.cc/terms/ctdna/> .